Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT01753414 (POSTILV) für Nicht-kleinzelliger Lungenkrebs ist aktiv, nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC (POSTILV) Phase 2 44 Randomisiert
POSTILV: A RANDOMIZED PHASE II TRIAL IN PATIENTS WITH OPERABLE STAGE I NON-SMALL CELL LUNG CANCER: RADICAL RESECTION VERSUS ABLATIVE STEREOTACTIC RADIOTHERAPY - This is a Limited Participation Study.
- POSTILV
- RF-3502
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
AndereSurgery R0 resection (radical resection) with nodal dissection or sampling (RODS). | Chirurgie Radical resection |
ExperimentellStereotactic Body Radiation Therapy (SBRT) Stereotactic Body Radiation Therapy (SBRT) given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days. | Stereotactic Body Radiation Therapy (SBRT) Daily fractions |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Percentage of Participants Alive Without Local-regional Failure at Two Years (Local-regional Tumor Control) | Local-regional failure (LRF) is defined differently for each arm. LRF after RODS is defined as recurrence, defined by CT, confirmed by PET/CT whenever possible, i.e., development of tumor masses at site of resection, hilum (N1 nodal region), mediastinum (N2-N3 nodes), ipsilateral supraclavicular fossa for upper lobe tumors (N3 nodes), or within 3 cm of the staple line of RODS. LRF after SBRT is defined as tumor progression on CT per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, confirmed by positron PET/CT, within same lobe, hilum (N1 nodes), mediastinum (N2-N3 nodes), or ipsilateral supraclavicular fossa for upper lobe tumors (N3 nodes), or within 3 cm of original planning target volume (PTV). Local-regional control time is defined as time from randomization to the date of first LRF, death, or last known follow-up (censored), whichever occurred first. Rates are estimated using the Kaplan-Meier method. | From date of randomization to two years |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Overall Survival (Percentage of Participants Alive) | Overall survival rates are estimated by the Kaplan-Meier method. The distribution of DFS estimates between the two arms is compared using the log rank test. Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Two-year rates are provided. | From date of randomization to date of death or last follow-up. Maximum follow-up was 7.0 years. |
Percentage of Participants With Local-regional Failure (LRF) | LRF rates are estimated using the cumulative incidence method. LRF is defined differently for each arm. LRF after RODS is defined as recurrence, defined by CT, confirmed by PET/CT whenever possible, i.e., development of tumor masses at site of resection, hilum (N1 nodal region), mediastinum (N2-N3 nodes), ipsilateral supraclavicular fossa for upper lobe tumors (N3 nodes), or within 3 cm of the staple line of RODS. LRF after SBRT is defined as tumor progression on CT per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, confirmed by PET/CT, within same lobe, hilum (N1 nodes), mediastinum (N2-N3 nodes), or ipsilateral supraclavicular fossa for upper lobe tumors (N3 nodes), or within 3 cm of original PTV. LRF time is defined as time from randomization to the date of first LRF, last known follow-up (censored), or death without LRF (competing risk), whichever occurred first. Two-year rates are provided. | From date of randomization to the date of first local-regional failure, death, or last known follow-up, whichever occurred first. Maximum follow-up is 7.0 years. |
Percentage of Participants With Distant Failure | Distant failure rates are estimated using the cumulative incidence method. Distant failure is defined as appearance of tumor within another ipsilateral (non-primary) lobe ≥ 2 cm from the original planning target volume (PTV) or distant metastasis, including appearance of tumor deposits characteristic of NSCLC metastasis (chest wall other than incision sites, mediastinal structures/diaphragm, malignant pleural/pericardial effusion), contralateral lung and/or other distant sites. Time to distant failure is defined as time from randomization to the date of first failure, last known follow-up (censored), or death without failure (competing risk). Two-year rates are provided. | From date of randomization to date of first distant failure, death, or last known follow-up, whichever occurred first. Maximum follow-up was 7.0 years. |
Percentage of Participants Alive Without Disease [Disease-free Survival (DFS)] | Failure rates are estimated using the Kaplan-Meier method, where failure is defined as LRF, DF, or death from any cause. LRF is defined differently for each arm. LRF after RODS is defined as recurrence, defined by CT, confirmed by PET/CT whenever possible, i.e., development of tumor masses at the resection site, hilum, mediastinum, or ipsilateral supraclavicular fossa for upper lobe tumors, or within 3 cm of the staple line of RODS. LRF after SBRT is defined as tumor progression on CT per RECIST criteria, confirmed by PET/CT, within same lobe, hilum, mediastinum, or ipsilateral supraclavicular fossa for upper lobe tumors, or within 3 cm of original PTV. DF is defined as tumor within a non-primary lobe ≥ 2 cm from the original planning target volume or distant metastasis. Failure time is defined as time from randomization to the date of first failure or last known follow-up (censored), whichever occurred first. Two-year rates are provided. | From date of randomization to the date of first failure, death, or last known follow-up, whichever occurred first. Maximum follow-up is 7.0 years. |
Number of Participants by Failure Site | Local-regional failure (LRF) is defined differently for each arm. LRF after RODS is defined as recurrence, defined by CT, confirmed by PET/CT whenever possible, i.e., development of tumor masses at site of resection, hilum, mediastinum, ipsilateral supraclavicular fossa for upper lobe tumors, or within 3 cm of the staple line of RODS. LRF after SBRT is defined as tumor progression on CT per RECIST criteria, confirmed by PET/CT, within same lobe, hilum, mediastinum, or ipsilateral supraclavicular fossa for upper lobe tumors, or within 3 cm of original planning target volume (PTV). Distant failure is defined as tumor within a non-primary lobe ≥ 2 cm from the original planning target volume or distant metastasis, including tumor deposits characteristic NSCLC metastasis (chest wall other than incision sites, mediastinal structures/diaphragm, malignant pleural/pericardial effusion), contralateral lung and/or other distant sites. | From date of randomization to date of last known follow-up. Maximum follow-up was 7.0 years. |
Best PET Tumor Response | PET Tumor Response of Irradiated Target Lesions is defined as
* Complete Metabolic Response (CMR): Tumor 18F-fluorodeoxyglucose (FDG)-activity decreased to less than mean background of the aortic arch blood pool.
* Partial Metabolic Response (PMR): At least a 30% decrease in the maximum of relative tumor FDG-activity of target lesions
* Progressive Metabolic Disease (PMD): At least a 20% increase in the maximum of relative tumor FDG-activity of target lesions
* Stable Metabolic Disease (SMD): Neither sufficient reduction to qualify for (major pathological response) PMR nor sufficient increase to qualify for PMD The percentage of decrease or increase was globally estimated based on readings of (tumor activity-aorta activity)/aorta activity. | From date of randomization to date of last known follow-up. Maximum follow-up was 7.0 years. |
Number of Participants by Highest Grade Adverse Event Reported | Common Terminology Criteria for Adverse Events (version 4.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. | From date of randomization to the date of last known follow-up. Maximum follow-up time was 7.0 years. |
Number of Participants With Surgical and Radiation Treatment Credentialing Completed and Documented Before Enrollment (Trial Feasibility) | baseline | |
Number of Eligible Participants (Trial Feasibility) | Goal: 95% of participants retain eligibility status (meet all eligibility criteria) after central review by headquarters staff. | Baseline |
Number of Participants With Baseline Forms Completed and Provided Within 30 Days of Randomization (Trial Feasibility) | Baseline | |
Number of Participants Lost to Follow-up (Trial Feasibility) | Goal: \< 3% of participants lost to follow-up. | From date of randomization to date of last known follow-up. Maximum follow-up was 7.0 years. |
- Pathologically (histologically or cytologically) proven diagnosis of Stage I NSCLC \[American Joint Committee on Cancer (AJCC), 7th ed.\], T1N0M0; note: T1N0 disease must be confirmed by FDG-PET/CT. (FDG = 18F-fluorodeoxyglucose; PET = positron emission tomography; CT = Computed Tomography)
Biopsy confirmation of diagnosis is strongly recommended but not required. If the biopsy is attempted and non-diagnostic, if the patient refuses biopsy, or if the risk of biopsy is considered too high, patients may be enrolled if the mass is suspicious for NSCLC based on 2 or more of the following criteria:
- Positive smoking history;
- Absence of benign calcifications within suspicious nodule;
- Activity on PET greater than normal tissue;
- Evidence of growth compared to previous imaging;
- Presence of spiculation.
The following primary cancer types are eligible: squamous cell carcinoma; adenocarcinoma; large cell carcinoma/ large cell neuroendocrine carcinoma; non-small cell carcinoma not otherwise specified.
Patients with hilar or mediastinal lymph nodes ≤ 1 cm and no abnormal hilar or mediastinal uptake on PET and CT will be considered N0. Mediastinal lymph node biopsy is required for patients with visible nodes: patients with > 1 cm hilar or mediastinal lymph nodes on CT or with nodes appearing as abnormal on PET (including suspicious but nondiagnostic uptake). Such patients will not be eligible unless directed biopsies of all abnormal lymph nodes are negative for cancer or these nodes demonstrate a lack of change during the prior 6 months and thus are considered to be non-malignant.
The patient must be considered a reasonable candidate for surgical resection using a lobectomy or pneumonectomy of the primary tumor within 6 weeks prior to registration, according to the following criteria based on the American College of Chest Physicians guidelines \[165\]:
- A qualified thoracic surgeon should make the determination that there would be a high likelihood of negative surgical margins;
- Baseline forced expiratory volume in 1 second (FEV1) >60% predicted, postoperative predicted FEV1 >40% predicted;
- Diffusion capacity of the lung for carbon monoxide (DLCO) >60% predicted, postoperative predicted DLCO > 40 % predicted;
- No baseline hypoxemia and/or hypercapnia;
- If the estimated postoperative FEV1 or DLCO <40% predicted indicates an increased risk for perioperative complications, including death, from a standard lung cancer resection (lobectomy or greater removal of lung tissue), then cardiopulmonary exercise testing to measure maximal oxygen consumption (VO2max) must be >60%;
- No severe pulmonary hypertension;
- No severe cerebral, acute or chronic cardiac, or peripheral vascular disease;
Pleural effusion, if present, must be deemed too small to tap under CT guidance and must not be evident on chest x-ray. Pleural effusion that appears on chest x-ray will be permitted only if there is no evidence of malignancy after invasive cytologic assessment.
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:
- History/physical examination, including documentation of weight within 6 weeks prior to registration;
- Evaluation by an experienced thoracic surgeon within 6 weeks prior to registration;
- FDG-PET/CT scan for staging and RT plan within 4 weeks prior to registration;
- CT scan (preferably with intravenous contrast, unless medically contraindicated) within 4 weeks prior to registration to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on CT scan.
Zubrod Performance Status 0-1 within 6 weeks prior to registration;
Age ≥ 18;
For women of childbearing potential, a serum or urine pregnancy test must be negative within 72 hours prior to registration;
Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment if assigned to treatment with SBRT.
Patients must provide study specific informed consent prior to study entry.
Direct evidence of regional or distant metastases after PET and surgical staging studies, or synchronous primary malignancy or prior invasive malignancy in the past 3 years, with the following exceptions:
- carcinoma in situ;
- early stage skin cancer that has been definitively treated;
- when an invasive malignancy has been treated definitively and the patient has remained disease free for ≥ 3 years;
Primary tumors >3 cm;
Prior systemic chemotherapy or thoracic surgery involving lobectomy or pneumonectomy;
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields;
Pure bronchioloalveolar carcinoma subtype of non-small cell lung cancer;
Active systemic, pulmonary, or pleural pericardial infection;
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
Radiation Therapy Oncology GroupVarian Medical Systems